EGFR and non-small cell lung carcinoma: In a similar study, researchers determined thattarget length (~200 bp) using a combined exoRNA and exoDNA resulted ingreater mutation detection for EGFR mutations in NSCLC patients than either exoDNAalone or cell-free DNA (cfDNA) (147).